CSL Shares Shift Positive YTD, As Resistance Turns To Support

CSL shares (ASX: CSL) are up 48.16% over the past month of trading, making one of the more dramatic recoveries on the ASX this year, in a remarkable return to YTD positive, albeit 0.28%. With various resistance levels falling by the wayside in recent weeks, what seemed almost unthinkable with the stock down 45% through the first five months of the year, is now a reality less than four months later. A glance at the 1 year chart below, and it is clear to see the stair steps lower, with a couple of recent elevators upwards.

[stock_market_widget type=“chart” template=“candlestick” assets=“CSL.AX” range=“1y” interval=“1d” price_field=“close” heading=“CSL Share Price (ASX: CSL) ” candle_border_width=“1” candle_bullish_background_color=“#21BA45” candle_bearish_background_color=“#DB2828” candle_bullish_border_color=“#21BA45” candle_bearish_border_color=“#DB2828” axes_color=“#000000” tooltip_text_color=“#262626” tooltip_background_color=“#FFFFFF” range_selector=“true” volume_enabled=“false” axes_enabled=“true” tooltip_enabled=“true” zoom_enabled=“true” save_image_enabled=“true” cursor_enabled=“true” api=“yahoo-finance”]

The latest leg higher (28% in the past seven trading sessions) traces back to CSL’s recent full-year result, which delivered an unusual combination of a statutory net loss of around US$2.5 billion, driven by US$7.1 billion in restructuring charges and impairments, alongside underlying earnings and revenue that came in above guidance and consensus.

Management framed FY26 as a deliberate reset year and guided to roughly 5% underlying net profit growth in FY27, with revenue broadly flat on the prior year. That framing gave investors something to work with: a cleaned-up balance sheet, a credible forward earnings base, and a dominant position in immunoglobulin and plasma markets where 2H26 Ig revenue accelerated at a double-digit pace.

From a multi-year low of A$90 reached in early June, the stock is approaching a doubling. This week is a continuation of that post-result momentum trade, the speed of which suggests that short-covering and underweight holders chasing benchmark exposure have played a meaningful role.

Looking to the analyst community, and they have not caught up with momentum. The average analyst target on CSL sits at A$162.92, roughly 6.5% below where the stock is trading, with a wide dispersion between more cautious targets in the low A$130s and bullish outliers near A$206. The current price implies the market is leaning hard toward the optimistic end of that range without the corresponding wave of formal upgrades having yet arrived.

The technical picture reinforces the sense that the stock is in a stretched but powerful trend. Price is trading above the upper Bollinger band, a signal that the recent range has been decisively broken to the upside and that volatility is expanding in the direction of the trend rather than reverting. The 14-period RSI is deep in overbought territory and the CCI is also pointing to an extended upside condition, consistent with a market that has shifted from value-driven buying into momentum-chasing.

With CSL’s share price moving into positive territory YTD, and some of the recent financials digested, it wouldn’t be against the grain to see some profit taking, or risk coming off with the technicals stretched. There could well be a further push towards retesting resistance at $180 if broader tailwinds emerge, yet for now this is one that could potentially do with a period of cooling whilst buyers re-form.